{
    "relation": [
        [
            "Company",
            "MBIA (NYSE:MBI)",
            "TOP Tankers (NASDAQ:TOPT)",
            "Genentech (NYSE:DNA)",
            "US Airways (NYSE:LCC)",
            "Brookfield Homes (NYSE:BHS)"
        ],
        [
            "Closing Price",
            "$27.42",
            "$3.21",
            "$66.29",
            "$18.04",
            "$15.69"
        ],
        [
            "CAPS Rating (5 max)",
            "*",
            "**",
            "****",
            "*",
            "*"
        ],
        [
            "% Change",
            "(15.97%)",
            "(15.75%)",
            "(8.92%)",
            "(8.05%)",
            "(4.15%)"
        ],
        [
            "52-Week Range",
            "$25.84-$76.02",
            "$3.03-$8.40",
            "$65.54-$89.73",
            "$17.86-$62.70",
            "$13.50-$41.49"
        ]
    ],
    "pageTitle": "Wednesday's Worst Stocks in the World (BHS.DL, MBI)",
    "title": "",
    "url": "http://www.fool.com/investing/general/2007/12/06/wednesdays-worst-stocks-in-the-world.aspx",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 0,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987135.9/warc/CC-MAIN-20150728002307-00296-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 450288823,
    "recordOffset": 450263290,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{25586=By Tim Beyers | More Articles December 6, 2007 | Comments (0)}",
    "TableContextTimeStampAfterTable": "{3353=Here's why that's bad: Press reports say that doctors often turn to Avastin \"off label,\" and in concert with chemotherapy, as a treatment for certain kinds of breast cancer. That may have contributed to a massive 54% spike in U.S. sales of Avastin, which, at $1.75 billion, accounted for nearly one-fifth of Genentech's 2006 revenue., 22484=Tim Beyers first began writing for the Fool in 2003. Today, he's an analyst for Motley Fool Rule Breakers and Motley Fool Supernova. At Fool.com, he covers disruptive ideas in technology and entertainment, though you'll most often find him writing and talking about the business of comics. Find him online at timbeyers.me or send email to tbeyers@fool.com. For more insights, follow Tim on Google+ and Twitter., 5629=But that still leaves Kerrigan with 121,206 shares, according to this Form 4 filing. Not bad, right? Not at all. But I find it interesting that Kerrigan owned 306,825 shares as of Feb. 15. Anyone else see an inconsistency here? Do the math with me: 306,825-139,000 = 167,825., 6029=Looking at footnote 2 on page 6 of the latest proxy shows that the \"missing\" 47,000 or so shares are unexercised options. Even so, were we to add them back in, it's fair to say that -- since February -- Kerrigan has cut his stake by roughly 46%., 20694=DocumentId: 548198, ~/Articles/ArticleHandler.aspx, 7/30/2015 2:23:27 AM}",
    "textBeforeTable": "Here are five stocks whose naughty ways drew investors' scorn on Wednesday: Bad days. We all have them; some of us deserve them. | More Articles December 6, 2007 | Comments (0) By Tim Beyers Wednesday's Worst Stocks in the World 0 Recs Print Email } console.log(\"Something went wrong!\"); // Do something if web service not working { function errorResponse() } }.bind(this), 2000); $(this).update('View My Articles') console.log(this); { timer = setTimeout(function() var timer; // Remove and insert view link after 2 seconds }); \"class\": \"saved\" \"href\": \"/myarticles\", $(this).writeAttribute({ { function successResponse() } $(this).writeAttribute({\"class\": \"saving\"}); $(this).update(\"Saving Article...\"); { function createResponse() }); }); }); onFailure: errorResponse onComplete: successResponse.bind(element), onCreate: createResponse.bind(element), parameters: pars, method: 'post', { url, var myAjax = new Ajax.Request( pars += '&item=' + 'http://www.fool.com/investing/general/2007/12/06/wednesdays-worst-stocks-in-the-world.aspx'; pars += \"headline=\" + \"Wednesday's Worst Stocks in",
    "textAfterTable": "Sources: The Wall Street Journal, Yahoo! Finance, Motley Fool CAPS. Naughty? Well, OK, we can't exactly call these stocks naughty. But none of them gets much love from our 76,000-person-strong Motley Fool CAPS community of amateur and professional stock pickers. To the contrary -- when it comes to these stocks, CAPS investors have gone thumbs down more often than film critic Roger Ebert. They believe that none of these stocks are worth owning and that some may be worth shorting. Which of today's candidates is worst? Read on, dear Fool. Worse We begin with Genentech, a four-star stock you'll not often find on this list. Here's why it makes the cut today: An FDA advisory panel has recommended that regulators not add breast cancer to the list of ailments for which its drug Avastin may serve as a treatment. Here's why that's bad: Press reports say that doctors often turn to Avastin \"off label,\" and in concert with chemotherapy, as a treatment for certain kinds of breast cancer. That may have contributed to a massive 54% spike in U.S. sales of Avastin, which, at $1.75 billion, accounted for nearly one-fifth of Genentech's 2006 revenue. Now, here's why Genentech isn't further down on today's list: For as much as Genentech depends on Avastin, the stock trades at a price-to-earnings ratio that's about even with its projected long-term growth rate and has a",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}